Beam Non Operating Income Net Other from 2010 to 2026
| BEAM Stock | USD 27.92 0.30 1.09% |
Non Operating Income Net Other | First Reported 2010-12-31 | Previous Quarter 19.6 M | Current Value 17.5 M | Quarterly Volatility 1.2 M |
Check Beam Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Beam Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.5 M, Interest Expense of 59.3 M or Selling General Administrative of 134.7 M, as well as many indicators such as Price To Sales Ratio of 35.11, Dividend Yield of 0.0 or PTB Ratio of 2.63. Beam financial statements analysis is a perfect complement when working with Beam Therapeutics Valuation or Volatility modules.
Beam | Non Operating Income Net Other | Build AI portfolio with Beam Stock |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Beam Therapeutics Correlation against competitors. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Will Biotechnology sector continue expanding? Could Beam diversify its offerings? Factors like these will boost the valuation of Beam Therapeutics. Projected growth potential of Beam fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Beam Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.41) | Revenue Per Share | Quarterly Revenue Growth (0.32) | Return On Assets | Return On Equity |
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Beam Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Beam Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Beam Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.